Kevin J Carroll
Overview
Explore the profile of Kevin J Carroll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
DCosta M, Kausz A, Carroll K, Ingimarsson J, Enders F, Mara K, et al.
Nephrol Dial Transplant
. 2020 Dec;
36(12):2208-2215.
PMID: 33367720
Background: Data directly demonstrating the relationship between urinary oxalate (UOx) excretion and stone events in those with enteric hyperoxaluria (EH) are limited. Methods: We assessed the relationship between UOx excretion...
12.
Ouyang J, Zhang P, Carroll K, Lee J, Koch G
J Biopharm Stat
. 2019 Dec;
30(4):593-606.
PMID: 31829826
A clinical trial often has primary and secondary endpoints and comparisons of high and low doses of a study drug to a control. Multiplicity is not only caused by the...
13.
Brandenburg V, Sinha S, Torregrosa J, Garg R, Miller S, Canals A, et al.
J Nephrol
. 2019 Aug;
32(5):811-821.
PMID: 31401795
Background: Calciphylaxis in end-stage renal disease is characterized by painful necrotic skin ulcers and high mortality. There are no approved therapies. SNF472, an intravenous formulation of myo-inositol hexaphosphate, inhibits the...
14.
Carroll K, Harvey-Vince L, Jenkins C, Mohan K, Balasegaram S
J Med Microbiol
. 2019 Apr;
68(6):930-939.
PMID: 30994441
Purpose: This study describes the epidemiology of Shiga toxin-producing Escherichia coli (STEC) infections in a population in the South East of England. Methods: From 1 November 2013 to 31 March...
15.
Benet L, Jayachandran P, Carroll K, Burmeister Getz E
Clin Pharmacol Ther
. 2019 Jan;
105(2):326-328.
PMID: 30652313
No abstract available.
16.
Ouyang J, Carroll K, Koch G, Li J
Pharm Stat
. 2017 May;
16(4):250-266.
PMID: 28470952
Missing data cause challenging issues, particularly in phase III registration trials, as highlighted by the European Medicines Agency (EMA) and the US National Research Council. We explore, as a case...
17.
Dalgleish A, Stebbing J, Adamson D, Arif S, Bidoli P, Chang D, et al.
Br J Cancer
. 2016 Oct;
115(9):e16.
PMID: 27727233
No abstract available.
18.
Dalgleish A, Stebbing J, Adamson D, Arif S, Bidoli P, Chang D, et al.
Br J Cancer
. 2016 Sep;
115(7):789-96.
PMID: 27599039
Background: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with gemcitabine...
19.
Inker L, Mondal H, Greene T, Masaschi T, Locatelli F, Schena F, et al.
Am J Kidney Dis
. 2016 Apr;
68(3):392-401.
PMID: 27032886
Background: The role of change in proteinuria as a surrogate end point for randomized trials in immunoglobulin A nephropathy (IgAN) has previously not been thoroughly evaluated. Study Design: Individual patient-level...
20.
Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
Carroll K
J Biopharm Stat
. 2013 Aug;
23(5):1188-200.
PMID: 23957523
With Phase III failure rates of 50%, better ways of predicting late-stage success are needed. One concept that has been used is "assurance." Rather than conventional power calculations hypothesizing a...